Press coverage about CymaBay Therapeutics (NASDAQ:CBAY) has been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. CymaBay Therapeutics earned a media sentiment score of 0.10 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 44.2593178029314 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the media stories that may have impacted Accern Sentiment Analysis’s rankings:
CymaBay Therapeutics (NASDAQ CBAY) traded down $0.04 during trading on Wednesday, reaching $13.46. The company’s stock had a trading volume of 1,851,094 shares, compared to its average volume of 977,812. CymaBay Therapeutics has a 52 week low of $2.31 and a 52 week high of $14.15. The stock has a market capitalization of $590.41, a PE ratio of -13.33 and a beta of 2.04. The company has a debt-to-equity ratio of 0.04, a quick ratio of 7.39 and a current ratio of 7.39.
Several equities analysts have commented on the company. ValuEngine raised CymaBay Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. HC Wainwright reissued a “buy” rating and set a $18.00 price target (up previously from $12.00) on shares of CymaBay Therapeutics in a research report on Wednesday, January 24th. BidaskClub raised CymaBay Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, January 26th. Leerink Swann reissued a “buy” rating and set a $16.00 price target on shares of CymaBay Therapeutics in a research report on Tuesday, November 28th. Finally, Evercore ISI started coverage on CymaBay Therapeutics in a research report on Tuesday. They set an “outperform” rating on the stock. Two analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $16.56.
In other news, Director Kurt Von Emster sold 4,300 shares of the firm’s stock in a transaction dated Friday, January 5th. The stock was sold at an average price of $10.21, for a total value of $43,903.00. Following the completion of the transaction, the director now directly owns 90,000 shares in the company, valued at $918,900. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Over the last 90 days, insiders sold 746,730 shares of company stock valued at $8,089,910. Company insiders own 15.10% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This report was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another site, it was illegally copied and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be read at https://www.dispatchtribunal.com/2018/02/14/cymabay-therapeutics-cbay-earns-coverage-optimism-rating-of-0-10.html.
CymaBay Therapeutics Company Profile
CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.
Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.